Overview

Artemisinin is a sesquiterpene lactone compound (C₁₅H₂₂O₅) isolated from the plant Artemisia annua (sweet wormwood), a herb long used in Traditional Chinese Medicine known as qinghao. Its discovery in 1972 by Chinese pharmaceutical chemist Tu Youyou — as part of the secret military research initiative "Project 523" — revolutionized the treatment of malaria and earned her a share of the 2015 Nobel Prize in Physiology or Medicine. The key structural feature of artemisinin is its unusual endoperoxide bridge (1,2,4-trioxane ring), which is essential for its antimalarial activity and distinguishes it from all other classes of antimalarial drugs.

The antimalarial mechanism centers on the endoperoxide bridge, which is activated by heme iron released during hemoglobin digestion within the Plasmodium parasite. This activation generates reactive oxygen species and carbon-centered free radicals that damage parasite proteins, lipids, and membranes, rapidly killing the organism. Artemisinin and its semisynthetic derivatives — dihydroartemisinin, artemether, and artesunate — form the basis of artemisinin-based combination therapies (ACTs), which the World Health Organization recommends as the first-line treatment for Plasmodium falciparum malaria worldwide. These compounds are valued for their rapid onset of action, broad-stage parasite killing, and relatively low toxicity.

A major concern in global malaria control is the emergence of artemisinin resistance, primarily associated with mutations in the Plasmodium falciparum Kelch13 protein, first identified in Southeast Asia and now spreading to other regions. Beyond antimalarial applications, artemisinin derivatives have shown promising pharmacological activities in preclinical research, including anticancer effects through induction of apoptosis and ferroptosis, anti-inflammatory properties, and antiviral activity. Ongoing research continues to explore novel therapeutic applications and strategies to overcome emerging drug resistance.

Mechanism of Action

Endoperoxide Bridge Activation

Artemisinin is a sesquiterpene lactone derived from Artemisia annua containing a unique 1,2,4-trioxane endoperoxide bridge essential for its antimalarial activity. Inside the parasitized erythrocyte, ferrous iron (Fe²⁺) from heme — liberated during hemoglobin digestion by Plasmodium — cleaves the endoperoxide bridge via reductive scission, generating cytotoxic carbon-centered free radicals and reactive oxygen species (ROS) (PMID: 15518585).

Heme Alkylation & Protein Damage

The carbon radicals produced by endoperoxide cleavage alkylate heme and parasite proteins, disrupting essential cellular processes. Key targets include the SERCA-type calcium ATPase (PfATP6), disrupting calcium homeostasis in the parasite's endoplasmic reticulum, and phosphatidylinositol 3-kinase (PfPI3K), impairing vesicular trafficking and lipid metabolism (PMID: 12853456).

Mitochondrial & Membrane Disruption

Artemisinin-derived radicals also attack parasite mitochondrial electron transport chain components, collapsing the mitochondrial membrane potential and triggering oxidative damage to lipid membranes. This multi-target oxidative assault results in rapid parasiticidal activity across all intraerythrocytic stages, including the ring stage, which is critical for preventing progression to severe malaria (PMID: 16101480).

Anti-Cancer Mechanisms

Beyond antimalarial activity, artemisinin shows selective cytotoxicity toward iron-loaded cancer cells through the same iron-dependent radical generation. It inhibits angiogenesis via downregulation of VEGF and disrupts the NF-kB and Wnt/beta-catenin pathways, inducing apoptosis and cell cycle arrest in various tumor models (PMID: 22185819).

Anti-Inflammatory Properties

Artemisinin suppresses NLRP3 inflammasome activation and inhibits NF-kB-mediated transcription of TNF-alpha, IL-6, and IL-1beta, contributing to anti-inflammatory effects investigated in autoimmune conditions.

Reconstitution Calculator

Research

Safety Profile

Common Side Effects

• Gastrointestinal: Nausea, vomiting, abdominal pain, diarrhea (very common, dose-related)
• Dizziness and headache
• Tinnitus (ringing in the ears)
• Pruritus (itching)
• Fatigue and asthenia
• Dark urine discoloration (harmless)

Serious Adverse Reactions

• Neurotoxicity: Artemisinin and its derivatives can cause cerebellar and brainstem toxicity at high or prolonged doses. Symptoms include ataxia, slurred speech, hearing loss, and nystagmus. This is well-documented in animal studies and case reports in humans with non-malarial (off-label) use.
• QT prolongation: Artemisinin combination therapies (ACTs) have been associated with cardiac conduction changes. ECG monitoring recommended per WHO guidelines.
• Hepatotoxicity: Elevated transaminases reported; rare cases of drug-induced liver injury.
• Hemolytic anemia: Can trigger hemolysis in G6PD-deficient patients.
• Type I hypersensitivity: Anaphylaxis reported rarely.

Contraindications

• Known hypersensitivity to artemisinin or sesquiterpene lactones
• First trimester of pregnancy (embryotoxic and teratogenic in animal studies; WHO advises avoidance in first trimester unless no alternative exists for severe malaria)
• Severe hepatic impairment
• G6PD deficiency (increased hemolysis risk)
• Cardiac conduction disorders (long QT syndrome)

Drug Interactions

• CYP2B6 and CYP3A4: Artemisinin is a potent auto-inducer of its own metabolism and induces CYP2B6/3A4. May reduce levels of co-administered drugs metabolized by these enzymes.
• Anticoagulants (warfarin): May alter INR; mechanism unclear
• QT-prolonging agents: Additive risk of arrhythmia
• Antiretrovirals (efavirenz, nevirapine): Complex CYP interactions; may reduce antiretroviral efficacy
• Immunosuppressants: May alter immune function; use with caution post-transplant
• Iron supplements: Artemisinin generates reactive oxygen species via iron-mediated Fenton reaction; theoretical potentiation of both efficacy and toxicity

Special Populations

• Pediatric: WHO-approved ACTs are used in pediatric malaria; supplement-grade artemisinin is not standardized for children
• Pregnancy: Contraindicated in first trimester; second/third trimester use only for malaria under medical supervision
• Geriatric: Increased susceptibility to neurotoxicity and hepatotoxicity
• Renal impairment: Limited data; dose adjustment may be needed

Monitoring

• CBC with reticulocyte count (hemolysis surveillance)
• Liver function tests (baseline and periodic)
• ECG (QTc interval) before and during therapy
• Neurological assessment with prolonged or high-dose use
• G6PD screening before initiation

Pharmacokinetic Profile